9 completed, 2 terminated. 5 Phase 3, 3 Phase 2, 2 Phase 4, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Recombivax HB: new trials by email Literature Review of Recombivax HB trials Research Report on Recombivax HB
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine - RSV Immunization | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 2226 | 2024-05-13 | 2026-10-05 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Effects of Persistent Innate Immune Activation on Vaccine Efficacy Recombivax - Hepatitis C Infection | Phase 4 | Terminated | Rockefeller University | 24 | 2015-05-08 | 2020-03-04 |
| The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults Alendronate, Hepatitis B Vaccine, Placebo - Hepatitis B | Phase 1 | Completed | Massachusetts General Hospital | 28 | 2014-04-01 | 2016-10-21 |
| Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062) 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM - Hepatitis B | Phase 3 | Completed | Merck Sharp & Dohme LLC | 722 | 2011-11-29 | 2018-07-18 |
| A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057) Modified Process Hepatitis B Vaccine (Experimental), Hepatitis B Vaccine (Recombinant) - Hepatitis B | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1718 | 2006-10-06 | 2017-05-23 |
| Immunologic Memory (Supp. of ATN 024) Engerix B, Twinrix for ATN 024, Recombivax - HIV Infections | Phase 4 | Completed | University of North Carolina, Chapel Hill | 95 | 2005-08-01 | 2017-02-28 |
| Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths Recombivax, Twinrix - Hepatitis B | Phase 2 | Completed | University of North Carolina, Chapel Hill | 123 | 2004-02-01 | 2017-03-29 |
| A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003) AR51 (12, 10), PR51 (3, 10), PR51 (6, 10) - Bacterial Infections; Virus Diseases | Phase 2 | Completed | Merck Sharp & Dohme LLC | 756 | 2001-05-01 | 2015-10-30 |
| Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV, Hepatitis B vaccine - Pertussis, Tetanus | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 277 | 1999-01-01 | 2015-03-25 |
Hepatitis B (6) · Pneumococcal Infections (2) · Bacterial Infections (1) · Diphtheria (1) · HIV Infections (1) · Hepatitis C (1) · Poliomyelitis (1) · Tetanus (1) · Virus Diseases (1) · Whooping Cough (1)
Merck Sharp & Dohme LLC (5) · Sanofi Pasteur, a Sanofi Company (2) · University of North Carolina, Chapel Hill (2) · Massachusetts General Hospital (1) · Rockefeller University (1)
United States (7) · Puerto Rico (4) · Thailand (2) · Turkey (Türkiye) (2) · Canada (1) · Mexico (1)
Charles Rice, PhD (1) · Coleen K. Cunningham, MD (1) · Stephen Obaro, MBBS, PhD (1)
PMID 20173677, PMID 21134456, PMID 21552183, PMID 25540274, PMID 29553862, PMID 36522265, PMID 36621410, PMID 37846456
2018 (2), U19AI111825 (1)